

**What is Claimed is:**

1. A pharmaceutical formulation comprising salmeterol or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and budesonide or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.  
5
2. A pharmaceutical formulation according to claim 1 which is suitable for administration by inhalation.  
10
3. A pharmaceutical formulation according to claim 1 wherein the pharmaceutically acceptable carrier or excipient is lactose.
4. A pharmaceutical formulation according to claim 1 wherein the pharmaceutically acceptable carrier or excipient comprises 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane.  
15
5. A method for the prophylaxis or treatment of a clinical condition in a mammal for which a selective  $\beta_2$ -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated, which comprises administering a therapeutically effective amount of a pharmaceutical formulation according to claim 1.  
20
6. A method according to claim 6 wherein the clinical condition is a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection, and upper respiratory tract disease.  
25
7. A pharmaceutical formulation comprising salmeterol xinafoate and budesonide, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.  
30

8. A pharmaceutical formulation according to claim 7 which is suitable for administration by inhalation.

5 9. A pharmaceutical formulation according to claim 7 wherein the pharmaceutically acceptable carrier or excipient is lactose.

10 10. A pharmaceutical formulation according to claim 7 wherein the pharmaceutically acceptable carrier or excipient comprises 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane.

15 11. A method for the prophylaxis or treatment of a clinical condition in a mammal for which a selective  $\beta_2$ -adrenoreceptor agonist and/or antiinflammatory corticosteroid is indicated, which comprises administering a therapeutically effective amount of a pharmaceutical formulation according to claim 7.

20 12. A method according to claim 11 wherein the clinical condition is a disease associated with reversible airways obstruction selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection